CSLLY.US CSL Ltd

Healthcare Biotechnology USA Stocks
34.37 USD
Close of Nov 13, 2026
15.80 36.88
Market cap
USD 66.0B
P/E
-
P/B
4.49x
ROE
-17.5%
Dividend yield
2.05%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CSLLY.US undervalued?

Graham number

The Graham number of CSL Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CSL Ltd fundamental analysis

No fundamental analysis for CSL Ltd yet.

CSL Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CSL Ltd

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, mar…

Full company profile